✦ LIBER ✦

Prostate specific antigen progression after radical prostatectomy in African-American men versus White men

✍ Scribed by Mousumi Banerjee; Isaac J. Powell; Julie George; Debjit Biswas; Fernando Bianco; Richard K. Severson

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 90 KB
Volume: 94
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.10535

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

BACKGROUND

It is well established that African‐American men (AAM) have a worse mortality from prostate carcinoma (PC) than White men (WM). Outcome data for men treated with radical prostatectomy for clinically localized PC demonstrate more advanced tumors and higher biochemical recurrence rates among AAM compared with WM. The objective of the current study was to characterize the pattern of prostate specific antigen (PSA) progression by race in patients experiencing disease recurrence after undergoing radical prostatectomy. Racial differences in the pattern of rising PSA would warrant different intervention strategies for reducing the disproportionality in survival outcomes between the two racial groups.

METHODS

Between 1991–1996, 1080 consecutive men underwent radical prostatectomy for clinically localized PC at Wayne State University‐affiliated Harper Hospital. Two hundred forty‐one patients developed a biochemical recurrence on or before January, 1, 1999. The median follow‐up was 39 months. Longitudinal PSA profiles of 77 men who met the study inclusion criteria were analyzed. Average relative velocities of PSA were compared between AAM and WM. Linear mixed effects regression was used to test the hypothesis that, after adjusting for age, preoperative PSA, stage and grade of disease, PSA levels increase at a faster rate in AAM compared with WM.

RESULTS

The mean average relative velocity for AAM and WM experiencing a disease recurrence was 0.25 ng/mL and 0.11 ng/mL per month, respectively (P = 0.21). The relative rate of PSA increase in patients who developed a disease recurrence after radical prostatectomy was 18.9% per month for AAM and 16.3% per month for WM (P = 0.73).

CONCLUSIONS

DOI 10.1002/cncr.10535

📜 SIMILAR VOLUMES

Biochemical outcome after radical prosta

Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels

✍ Stephen J. Freedland; William J. Aronson; Christopher J. Kane; Martha K. Terris; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## Abstract ## BACKGROUND Recent studies have shown that a significant number of men with normal prostate‐specific antigen (PSA) levels have prostate carcinoma. Whether malignancies in such men are associated with better outcomes is unclear. The authors compared the risk of biochemical failure aft

Predictors of prostate-specific antigen

Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy

✍ Stephen J. Freedland; William J. Aronson; Joseph C. Presti Jr.,; Christopher L. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Abstract ## BACKGROUND Seminal vesicle (SV) invasion at the time of radical prostatectomy (RP) generally is considered to be indicative of poor outcome. The authors examined whether there was a subset of men with SV invasion who had long‐term prostate‐specific antigen (PSA) progression–free sur

Rosiglitazone versus placebo for men wit

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy

✍ Matthew R. Smith; Judith Manola; Donald S. Kaufman; Daniel George; William K. Oh 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to assess the biologic activity of rosiglitazone, a peroxisome proliferator‐activated receptor γ agonist that has been approved to treat type 2 diabetes, in men with recurrent prostate carcinoma using change in prostate specific antigen (PS

Improvements in pathologic staging for A

Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era : Implications for screening a high-risk group for prostate carcinoma

✍ Edmond L. Paquette; Roger R. Connelly; Isabell A. Sesterhenn; Wei Zhang; Leon Su 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB 👁 2 views

Natural history of disease progression i

Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy

✍ Craig G. Rogers; Masood A. Khan; M. Craig Miller; Robert W. Veltri; Alan W. Part 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB 👁 1 views

Prostate cancer-specific mortality after

Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors

✍ Anthony V. D'Amico; Ming-Hui Chen; William J. Catalona; Leon Sun; Kimberly A. Ro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 292 KB

## Abstract ## BACKGROUND. Estimates of prostate cancer‐specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with ≥1 high‐risk factors. ## METHODS. The study cohort comprised 948 men who underwent RP (N = 660) or RT (N = 288) for localized p